Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers

Bibliography

• Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer 2004;4:737-47
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm–general principles. Nat Clin Pract Oncol 2007;4:86-100
   PubMedGoogle Scholar
• Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 2007;4:172-180
   PubMedGoogle Scholar
• Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 2007;19:397-417
   PubMed Web of Science ®Google Scholar
• Oehler C, Dickinson DJ, Broggini-Tenzer A, et al. Current concepts for the combined treatment modality of ionizing radiation with anticancer agents. Curr Pharm Des 2007;13:519-35
   PubMed Web of Science ®Google Scholar
• Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol 2007;25:4043-50
   PubMed Web of Science ®Google Scholar
• Ben-Josef E. Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer. Am J Clin Oncol 2007;30:649-55
   Google Scholar
• Nukatsuka M, Fujioka A, Nakagawa F, et al. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol 2004;25:1531-6
   Google Scholar
• Nakata E, Fukushima M, Takai Y, et al. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU. Oncol Rep 2006;16:465-71
   Google Scholar
• Taiho Pharmaceutical Co. Radiotherapy enhancer. EP1864683; 2007
   Google Scholar
• Taiho Pharmaceutical Co. Potentiator for radiation therapy comprising pyridine derivative as active ingredient. EP1864974; 2007
   Google Scholar
• Tsujinaka T, Fujitani K, Hirao M, et al. Current status of chemoradiotherapy for gastric cancer in Japan. Int J Clin Oncol 2008;13:117-20
   Google Scholar
• Clinical Trials. Available from: www.clinicaltrials.gov
   Google Scholar
• Saif MW, Berk G, Cheng YC, et al. IPdR: a novel oral radiosensitizer. Expert Opin Invest Drugs 2007;16:1415-24
   PubMed Web of Science ®Google Scholar
• University of Miami. Designer therapy of pancreatic tumors. WO2008085611; 2008
   Google Scholar
• Kazuno H, Shimamoto Y, Tsujimoto H, et al. Mechanism of action of a new antitumor ribonucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), differs from that of 5-fluorouracil. Oncol Rep 2007;17:1453-60
   Google Scholar
• Yasui H, Inanami O, Asanuma T, et al. Treatment combining X-irradiation and a ribonucleoside anticancer drug, TAS106, effectively suppresses the growth of tumor cells transplanted in mice. Int J Radiat Oncol Biol Phys 2007;68:218-28
   PubMed Web of Science ®Google Scholar
• Yasui H, Ogura A, Asanuma T, et al. Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo. Br J Cancer 2008;99:1442-52
   Google Scholar
• Taiho Pharmaceutical Co. L. 3′-ethynylcytidine derivative. WO2008012945; 2008
   Google Scholar
• Anderson P, Aguilera D, Pearson M, et al. Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control 2008;15:38-46
   PubMedGoogle Scholar
• Flanagan SA, Robinson BW, Krokosky CM, et al. Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers. Mol Cancer Ther 2007;6:1858-68
   PubMed Web of Science ®Google Scholar
• Jordheim L, Galmarini CM, Dumontet C. Recent developments to improve the efficacy of cytotoxic nucleoside analogs. Recent Patents Anticancer Drug Discov 2006;1:163-70
   Google Scholar
• Clavis Pharma AS. Oral dosage forms of gemcitabine derivatives. WO2006098628; 2006
   Google Scholar
• Southern Research Institute. Methods for treating neoplasia with combination of chemotherapeutic agents and radiation. WO2008128170; 2008
   Google Scholar
• Cariveau MJ, Stackhouse M, Cui XL, et al. Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response. Int J Radiat Oncol Biol Phys 2008;70:213-20
   Web of Science ®Google Scholar
• Barker CA, Burgan WE, Carter DJ, et al. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine- 2-carboxaldehyde-thiosemicarbazone). Clin Cancer Res 2006;12:2912-8
   PubMed Web of Science ®Google Scholar
• US Government. Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents. WO2007035489; 2007
   Google Scholar
• Kil WJ, Cerna D, Burgan WE, et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 2008;14:931-8
   PubMedGoogle Scholar
• Nieder C, Adam M, Grosu AL. Combined modality treatment of glioblastoma multiforme: the role of temozolomide. Rev Recent Clin Trials 2006;1:43-51
   Google Scholar
• Trivedi RN, Wang XH, Jelezcova E, et al. Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. Mol Pharmacol 2008;74:505-16
   Google Scholar
• University of Pittsburgh, Sobol R. Inhibiting DNA polymerase beta to enhance efficacy of anticancer agents. WO2007001684; 2007
   Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84
   PubMed Web of Science ®Google Scholar
• Hermann RM, Rave-fränk M, Pradier O. Combining radiation with oxaliplatin: a review of experimental results. Cancer Radiother 2008;12:61-7
   Google Scholar
• Pola Chemical Industry, Inc. Agent for reinforcing radiation-sensitizing ability in hypoxic cell radiation sensitizer. JP2007302609; 2007
   Google Scholar
• Momekov G, Momekova D. Recent developments in antitumour platinum coordination compounds. Expert Opin Ther Patents 2006;16:1383-403
   Web of Science ®Google Scholar
• Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz Z. Broken beyond repair. Damaging DNA in glioblastoma cells with radiation and camptothecin. Cancer Biol Ther 2008;7:374-5
   PubMed Web of Science ®Google Scholar
• Kitasato Gakuen Foundation. Chemoradiotherapy with TS-1/camptothecins. US2007036717; 2007
   Google Scholar
• California Pacific Medical Center, Catholic Healthcare West. Camptothecin derivatives as chemoradiosensitizing agents. WO2007048002; 2007
   Google Scholar
• Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:928-42
   PubMed Web of Science ®Google Scholar
• Florida State University. Radiosensitizing taxanes and their pharmaceutical preparations. US7067552; 2006
   Google Scholar
• American Bioscience, Inc. Combinations and modes of administration of therapeutic agents and combination therapy. WO2006089290; 2006
   Google Scholar
• Wiedenmann N, Valdecanas D, Hunter N, et al. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res 2007;13:1868-74
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Coudert B, Isambert N, et al. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007;18(Suppl 5):v9-15
   PubMed Web of Science ®Google Scholar
• Hofstetter B, Vuong V, Broggini-tenzer A, et al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 2005;11:1588-96
   PubMed Web of Science ®Google Scholar
• Novartis AG. Treatment of proliferative diseases with epothilone derivatives and radiation. EP1605937; 2005
   Google Scholar
• Brown JM. The hypoxic cell: a target for selective cancer therapy – Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1999;59:5863-70
   PubMed Web of Science ®Google Scholar
• Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol 2007;435:297-321
   PubMed Web of Science ®Google Scholar
• Bache M, Kappler M, Said HM, et al. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem 2008;15:322-38
   PubMed Web of Science ®Google Scholar
• Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007;25:4066-74
   PubMed Web of Science ®Google Scholar
• Allos Therapeutics Inc. Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer. US2007259966; 2007
   Google Scholar
• Spectrum Pharmaceuticals, Inc., Trustees of the University of Illinois. Sensitization of tumour cells to radiation therapy through the administration of endothelin agonists, WO2008027839; 2008
   Google Scholar
• Mckeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol) 2007;19:427-42
   PubMed Web of Science ®Google Scholar
• Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007;12:853-9
   PubMed Web of Science ®Google Scholar
• Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007;26:341-52
   PubMed Web of Science ®Google Scholar
• Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008;8:705-13
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-37
   PubMed Web of Science ®Google Scholar
• Weinmann M, Welz S, Bamberg M. Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology. Curr Med Chem Anticancer Agents 2003;3:364-74
   PubMedGoogle Scholar
• Nagasawa H, Uto Y, Kirk KL, et al. Design of hypoxia-targeting drugs as new cancer chemotherapeutics. Biol Pharm Bull 2006;29:2335-42
   PubMed Web of Science ®Google Scholar
• Murata R, Tsujitani M, Horsman MR. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiother Oncol 2008;87:331-8
   Google Scholar
• Nishimura Y, Nakagawa K, Takeda K, et al. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002). Int J Radiat Oncol Biol Phys 2007;69:786-92
   Google Scholar
• Karasawa K, Sunamura M, Okamoto A, et al. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study. Radiother Oncol 2008;87:326-30
   PubMed Web of Science ®Google Scholar
• Pola Chemical Industry, Inc. Treatment for cancer having resistance to radiotherapy. JP2007326814; 2007
   Google Scholar
• Pola Chemical Industry, Inc. Enhancer of radiosensitization ability in hypoxic cell radiosensitizer. JP2007230958; 2007
   Google Scholar
• University Alberta. Novel substituted 2-nitroimidazoles useful for hypoxic cell therapy and imaging. WO2006102759; 2006
   Google Scholar
• Emami S, Kumar P, Yang J, et al. Synthesis, transportability and hypoxia selective binding of 1-beta-D-(5-Deoxy- 5-fluororibofuranosyl)-2-nitroimidazole (beta-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA. J Pharm Pharm Sci 2007;10:237-45
   PubMedGoogle Scholar
• Nakae T, Uto Y, Tanaka M, et al. Design, synthesis, and radiosensitizing activities of sugar-hybrid hypoxic cell radiosensitizers. Bioorg Med Chem 2008;16:675-82
   Google Scholar
• Matthews RH. Radiosensitizer formulations comprising nitrohistidine derivatives. WO2006078903; 2006
   Google Scholar
• Wardman P, Rothkamm K, Folkes LK, et al. Radiosensitization by nitric oxide at low radiation doses. Radiat Res 2007;167:475-84
   PubMed Web of Science ®Google Scholar
• De Ridder M, Verellen D, Verovski V, et al. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide 2008;19:164-9
   PubMed Web of Science ®Google Scholar
• Duke University. Use of an agent that restores tissue perfusion and oxygenation. WO2006113540; 2006
   Google Scholar
• Sonveaux P, Lobysheva II, Feron O, et al. Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery. Physiology (Bethesda) 2007;22:97-112
   Google Scholar
• Coulter JA, Mccarthy HO, Worthington J, et al. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Ther 2008;15:495-503
   Google Scholar
• Li F, Sonveaux P, Rabbani ZN, et al. Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 2007;26:63-74
   PubMed Web of Science ®Google Scholar
• Evans JW, Chernikova SB, Kachnic LA, et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res 2008;68:257-65
   PubMedGoogle Scholar
• Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 2009;18:77-87
   PubMed Web of Science ®Google Scholar
• Denny WA. Hypoxia-activated anticancer drugs. Exp Opin Ther Patents 2005;15:635-46
   Web of Science ®Google Scholar
• Hicks KO, Pruijn FB, Secomb TW, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 2006;98:1118-28
   PubMed Web of Science ®Google Scholar
• Auckland Uniservices Ltd. Novel 1,2,4-benzotriazine-1,4-dioxides. WO2005082867; 2005
   Google Scholar
• Hay MP, Hicks KO, Pruijn FB, et al. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. J Med Chem 2007;50:6392-404
   PubMed Web of Science ®Google Scholar
• Auckland Uniservices Ltd. Tricyclic 1,2,4-triazine oxides and compositions therefrom for therapeutic use in cancer treatments. WO2006104406; 2006
   Google Scholar
• Hay MP, Hicks KO, Pchalek K, et al. Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. J Med Chem 2008;51:6853-65
   Google Scholar
• Hay MP, Atwell GJ, Wilson WR, et al. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase. J Med Chem 2003;46:2456-66
   PubMedGoogle Scholar
• Auckland Uniservices Ltd. Nitrobenzidoles and their use in cancer therapy. WO2006043839; 2006
   Google Scholar
• Auckland Uniservices Ltd. Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents. WO2005042471; 2005
   Google Scholar
• Patterson AV, Ferry DM, Edmunds SJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007;13:3922-32
   PubMed Web of Science ®Google Scholar
• Hicks KO, Myint H, Patterson AV, et al. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys 2007;69:560-71
   Google Scholar
• Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs. WO2007002931; 2007
   Google Scholar
• Duan JX, Jiao H, Kaizerman J, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008;51:2412-20
   PubMed Web of Science ®Google Scholar
• Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer. WO2008083101; 2008
   Google Scholar
• Kudos Pharmaceuticals, Inc. Process for the preparation of AQ4N. US2007161808; 2007
   Google Scholar
• Steward WP, Middleton M, Benghiat A, et al. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study. Ann Oncol 2007;18:1098-103
   Google Scholar
• Spectrum Pharmaceuticals Inc. Indoloquinone tumor radiation sensitization. WO2006105507; 2006
   Google Scholar
• Spectrum Pharmaceuticals Inc. Medical compositions for intravesical treatment of bladder cancer. US2007010570; 2007
   Google Scholar
• Seow HA, Penketh PG, Shyam K, et al. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells. Proc Natl Acad Sci USA 2005;102:9282-7
   Google Scholar
• Vion Pharmaceuticals, Inc. Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents. WO2006034266; 2006
   Google Scholar
• Maity A, Tuttle SW. 2-Deoxyglucose and radiosensitization: teaching an old DOG new tricks? Cancer Biol Ther 2006;5:824-6
   PubMed Web of Science ®Google Scholar
• Coleman MC, Asbury CR, Daniels D, et al. 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med 2008;44:322-31
   PubMed Web of Science ®Google Scholar
• Threshold Pharmaceuticals. Treatment of cancer with 2-deoxyglucose. WO2006124573; 2006
   Google Scholar
• Threshold Pharmaceuticals. Anti-cancer therapies. WO2007035961; 2007
   Google Scholar
• Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 2007;26:241-8
   PubMed Web of Science ®Google Scholar
• Zhang X, Kon T, Wang H, et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 2004;64:8139-42
   PubMed Web of Science ®Google Scholar
• Santaris Pharmaceuticals SA. Potent LNA oligonucleotides for the inhibition of HIF-1a expression. WO2006050734; 2006
   Google Scholar
• Prolx Pharmaceuticals Corp. Regulation of HIF protein levels via deubiquitination pathways. WO2005007828; 2005
   Google Scholar
• Welsh S, Williams R, Kirkpatrick L, et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004;3:233-44
   PubMed Web of Science ®Google Scholar
• Koh MY, Spivak-kroizman T, Venturini S, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 2008;7:90-100
   PubMed Web of Science ®Google Scholar
• Palayoor ST, Mitchell JB, Cerna D, et al. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 2008;123:2430-7
   PubMed Web of Science ®Google Scholar
• Schwartz D, OJ, Williams R, et al. Molecular-genetic image guided studies of the antitumor HIF-1α inhibitor PX-478 in combination with radiation. AARC meeting 2008 [Abstr 2566]
   Google Scholar
• Duke University. Inhibition of HIF-1 activation for antitumour and anti-inflammatory responses. WO2007123777; 2007
   Google Scholar
• US Government. Tricyclic compounds as inhibitors of the hypoxic signaling pathway. WO2005118580; 2005
   Google Scholar
• Creighton-gutteridge M, Cardellina JH, Stephen AG, et al. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res 2007;13:1010-8
   PubMedGoogle Scholar
• Rich JN. Cancer stem cells in radiation resistance. Cancer Res 2007;67:8980-4
   PubMed Web of Science ®Google Scholar